April 5, 2012

Correction of Postkidney Transplant Anemia Reduces Progression of Allograft Nephropathy

.   .   

In this randomized controlled trial, use of erythropoietin in renal transplant recipients to normalize hemoglobin to normal levels (130-150 g/L) resulted in less decline in graft function, less graft failure and fewer deaths compared to maintaining hemoglobin in the range recommended by current renal guidelines (105-115 g/L). This is a surprising result, as there have been several randomized controlled trials in chronic kidney disease and end-stage renal disease patients that have failed to show improved outcomes by targeting near-normal hemoglobin levels. This is a small study, and will likely need to be repeated with a large sample size in order to confirm these results.

Related Articles:

Renal Transplantation

Comments are closed.